FMR CORP 13D and 13G filings for Monte Rosa Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 10:32 am Sale |
2024-11-08 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 5,101,413 8.312% |
-435,826 (-7.87%) |
Filing |
| 2024-02-09 09:28 am Sale |
2024-02-08 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 5,537,239 11.056% |
-680,219 (-10.94%) |
Filing |
| 2023-02-09 12:01 pm Sale |
2023-02-09 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 6,217,458 12.846% |
-758,429 (-10.87%) |
Filing |
| 2022-02-09 09:22 am Purchase |
2022-02-08 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 6,975,887 14.999% |
803,610 (+13.02%) |
Filing |
| 2021-08-10 10:33 am Purchase |
2021-08-09 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
FMR CORP | 6,172,277 13.873% |
6,172,277 (New Position) |
Filing |